Scott Shellady, CEO of Bull Reef Brokerage at TJM Investments, comments on the U.S. market and says that it should continue to sell off if the jobs number come out strong.» Read More
AstraZeneca has the "critical mass" to succeed internationally, Pascal Soriot, CEO of AstraZeneca told CNBC, also discussing the group¿s pipeline.
Jason Kolbert, head of health care equity research at Maxim Group, says Pfizer's takeover bid is driven by AstraZeneca's pipeline, strategic tax advantages and cost savings.
Ian Read, CEO of Pfizer, says there is a "very strong industrial rationale" behind its AstraZeneca's takeover bid, as the groups' pipelines would both benefit from being combined.
Andrew Burkly, head of institutional portfolio strategy at Oppenheimer & Co., says the underlying fundamentals for U.S. equities remain "pretty constructive", and large cap stocks should outperform small caps this year.
Gerhard Roiss, CEO of OMV, discusses the impact of the Russian sanctions on European gas, and dismisses calls for a unified gas price across the region.
Scott Moeller, director of the M&A research centre at Cass Business School, discusses the potential AstraZeneca takeover and Pfizer's strategy.
Nicolas De Santis, president and secretary general at Gold Mercury International, says the European Union has an "identity problem" and needs a stronger brand and identity.
Christian Keller, head of emerging markets research at Barclays, says emerging market credit valuation is quite attractive but advises being "choosy and picky."
Chuka Umunna, U.K. shadow business secretary, says the potential AstraZeneca takeover by Pfizer should be looked at as of national economic interest, and that more should be done to protect R&D jobs.
Ranjith Gopinathan, program manager for life sciences and health care practice at Frost & Sullivan, explains why he believes the Pfizer/AstraZeneca deal would be positive.
Mebane Faber, CIO of Cambria Investment Management, discusses where to get the best-value equities now there are a lot of "very cheap" countries.
The European Union will not recognize the "pseudo-referendum" in eastern Ukraine says Radoslaw Sikorski, Polish foreign minister, adding that it also refuses to recognize the annexation of Crimea.
Pfizer is "back on the attack" and trying to make sure the takeover of AstraZeneca is seen as being "all about science and medicine", CNBC's Catherine Boyle reports.
Michael O'Sullivan, CIO for U.K. and EMEA at Credit Suisse Private Bank, discusses M&A activity and says it's now "running into reality" as governments, shareholders and investors are becoming more vocal.
Atul Goyal, senior analyst at Jefferies, says Sharp is facing intensifying competition, warning that the group will need to raise "a lot of equity" in the coming year.
John Hardy, foreign exchange strategist at Saxo Bank, says there's a "bearish reversal" for the euro, which could slip lower ahead of the ECB June meeting.
Antonin Jullier, global head of equity trading strategy at Citi, says global stock markets are "getting used" to the situation in Ukraine and discusses investing in equities.
Richard Kramer, managing partner at Arete Research, discusses Apple's potential acquisition of Beats and says this could be a "very profitable" business.
Robert Boland, academic chair and professor of sports management at NYU, comments on the NFL as the draft kicks off in New York on Friday.
Francesco Galietti, founder and CEO of Policy Sonar, says Silvio Berlusconi is likely to try and turn his community service into a political opportunity, and that his lack of official successor is hurting his Forza Italia party.